Convenient synthesis of nucleoside and isonucleoside analogues

Organic Letters

Volumn 7, Issue 11, 2005, Pages 2161-2164

  De Cienfuegos, Luis Álvarez ^a,b   Mota, Antonio J ^a,c   Robles, Rafael ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE DERIVATIVE; CARBON; CYTOSINE; FLUOROURACIL; NUCLEOSIDE DERIVATIVE; THEOPHYLLINE; THYMINE; URACIL;

ARTICLE; DRUG SYNTHESIS; STEREOCHEMISTRY; SUBSTITUTION REACTION;

CATALYSIS; CYTOSINE; INDICATORS AND REAGENTS; MOLECULAR STRUCTURE; NUCLEOSIDES; THYMINE; URACIL;

EID: 20444491980     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol050496v     Document Type: Article

References (38)

1. (a) Mitsuya, H.; Yarchoan, R.; Broker, S. Science 1990, 249, 1533-544.
2. (b) Herdewijn, P. A. M. M. Antiviral Res. 1992, 19, 1-14.
3. (a) St. Clair, M. H.; Martin, J. L.; Tudor-Williams, G.; Bach, M. C.; Vavro, C. L.; King, D. M.; Kellam, P.; Kemp, S. D.; Larder, B. A. Science 1991, 253, 1557-1559.
4. (b) De Clercq, E. Biochem. Pharmacol. 1994, 47, 155-169.
5. (a) Chen, C.-H.; Cheng, Y.-C. J. Biol. Chem. 1989, 264, 11934-11937.
6. (b) Chen, C.-H.; Valquez-Padua, M.; Cheng, Y.-C. Mol. Pharmacol. 1991, 39, 625-628.
7. (a) York, J. L. J. Org. Chem. 1981, 46, 2171-2173.
8. (b) Nair, V.; Buenger, G. S. J. Org. Chem. 1990, 55, 3695-3697.
9. (a) Bloch, A.; Robins, M. J.; McCarthy, J. R. J. Med. Chem. 1967, 10, 908-912.
10. (b) Cooney, D. A.; Ahluwalia, G.; Mitsuya, H.; Fridland, A.; Johnson, M.; Hao, Z.; Dajal, M.; Balzarini, J.; Broder, S.; Johns, D. G. Biochem. Pharmacol. 1987, 36, 1765-1768.
11. (c) Nair, V.; Sells, T. B. Biochim. Biophys. Acta 1992, 1119, 201-204.
12. (a) Herdewijn, P.; Balzarini, J.; De Clercq, E.; Pauwels, R.; Baba, M.; Broder, S.; VanderHeghe, H. J. Med. Chem. 1987, 30, 1270-1278.
13. (b) Mitsuya, H.; Yarchoan, R.; Broder, S. Science 1990, 249, 1533-1544.
14. (c) De Clercq, E. Design of Anti-AIDS Drugs; Elsevier: New York, 1990.
15. (a) Huryn, D. M.; Sluboski, B. C.; Tam, S. Y.; Weigele, M.; Sim, I.; Anderson, B. D.; Mitsuya, H.; Broder, S. J. Med. Chem. 1992, 35, 2347-2354.
16. (b) Verheggen, I.; Van Aerschot, A.; Van Meervelt, L.; Rozenski, J.; Wiebe, L.; Snoeck, R.; Andrei, G.; Balzarini, J.; Claes, P.; De Clercq, E.; Herdewijn, P. J. Med. Chem. 1995, 38, 826-835.
17. (c) Nair, V.; Jahnke, T. S. Antimicrob. Agents Chemother. 1995, 39, 1017-1029.
18. (d) Yu, H.-W.; Zhang, L.-R.; Zhou, J.-C; Ma, L.-T.; Zhang, L.-H. Bioorg. Med. Chem. 1996, 4, 609-614.
19. (e) Wang, J.-F.; Yang, X.-D.; Zhang, L.-R.; Yang, Z.-J.; Zhang, L.-H. Tetrahedron 2004, 60, 8535-8546.
20. (a) Jung, M. E.; Nichols, C. J. J. Org. Chem. 1998, 63, 347-355.
21. (b) Díaz, Y.; Bravo, F.; Castillón, S. J. Org. Chem. 1999, 64, 6508-6511.
22. (c) Bera, S.; Nair, V. Tetrahedron Lett. 2001, 42, 5813-5815.
23. (d) Lei, Z.; Zhang, L.; Zhang, L.-R.; Chen, J.; Min, J.-M.; Zhang, L.-H. Nucleic Acids Res. 2001, 29, 1470-1475.
24. (e) Chattopadhyay, A.; Salaskar, A. J. Chem. Soc., Perkin Trans. 1 2002, 785-789.
25. (f) Nair, V.; Chun, B.-K. Arkivoc 2003, i, 9-21.
26. (a) Robles, R.; Rodríguez, C.; Izquierdo, I.; Plaza, M. T.; Mota, A. Tetrahedron: Asymmetry 1997, 8, 2959-2965.
27. (b) Álvarez de Cienfuegos, L.; Mota, A. J.; Rodríguez, C.; Robles, R. Tetrahedron Lett. 2005, 46, 469-473.
28. (a) Álvarez de Cienfuegos, L.; Rodríguez, C.; Mota, A. J.; Robles, R. Org. Lett. 2003, 5, 2743-2745.
29. (b) Robles, R.; Rodríguez, C.; Álvarez de Cienfuegos, L.; Mota, A. J. Tetrahedron: Asymmetry 2004, 15, 831-838.
30. Robles, R.; Izquierdo, I.; Rodríguez, C.; Plaza, M. T.; Mota, A. J.; Álvarez de Cienfuegos, L. Tetrahedron: Asymmetry 2002, 13, 399-405.
31. Robles Díaz, R.; Rodríguez Melgarejo, C.; Izquierdo Cubero, I.; Plaza López-Espinosa, M. T. Carbohydr. Res. 1997, 300, 375-380.
32. Robles-Díaz, R.; Rodríguez Melgarejo, C.; Plaza López-Espinosa, M.-T.; Izquierdo Cubero, I. J. Org. Chem. 1994, 59, 7928-7929.
33. 2O (1 mL). After 10 min, TLC (ether) revealed that the reaction was finished, showing a lower-running product. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (1:1 ether/hexane), yielding 1 (0.85 mmol, 85%) as a mixture of anomers.
34. 2/MeOH) to yield respectively 5T, 5U, 5F, and 6, the latter being a ∼9:1 mixture of isomers (see Table 1).
35. Theophylline was chosen as a base because the absence of hydrogens should prohibit the tricycle formation, as it has been experimentally proved.
36. Hyperchem, release 7.5; Hypercube, Inc.: Gainesville, FL.
37. (a) Thedford, R.; Fleysher, M. H.; Hall, R. H. J. Med. Chem. 1965, 8, 486-491.
38. (b) Robles, R.; Rodríguez, C.; Izquierdo, I.; Plaza, M. T.; Mota, A.; Álvarez de Cienfuegos, L. Tetrahedron: Asymmetry 2000, 11, 3069-3077.